DiagnoCure Announces Changes to Its Board of Directors

Published: Nov 26, 2012

Two seasoned business leaders join the Board

QUEBEC CITY, Nov. 26, 2012 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) today announced that its Board of Directors has appointed two new members, effective immediately. The new directors are Dr. Jacques Simoneau, current President and Chief Executive Officer of Gestion Univalor L.P. and Mr. Andrew J. Sheldon, current President and Chief Executive Officer of Medicago. The two new directors will also stand for re-election at DiagnoCure's next annual meeting of shareholders.

"The addition of these new directors will further diversify the outstanding talents and wide-ranging experience that our directors already bring to DiagnoCure," said Dr. Yves Fradet, the Chairman of the Board. "Both are widely respected and experienced business leaders, and together they will provide our board and management team with new insight and perspectives relating to DiagnoCure's business and the rapidly changing diagnostics industry."

These appointments are made in the context of the retirement from the Board of Mr. Paul Gobeil, Mr. Alain Michel and Dr. Mario Thomas. Dr. Thomas has stepped down in order to focus on his other professional engagements while Messrs. Michel and Gobeil both say their decision is motivated by their recognition of the need to foster renewal on the Board.

"On behalf of DiagnoCure and its Board of Directors, we wish to thank Mr. Gobeil, Mr. Michel and Dr. Thomas for their devoted service and sound counsel, and we wish them the very best," said Dr. Yves Fradet, in his capacity as Chairman of the Board.

Dr. Simoneau has agreed to join and to chair the Audit and Risk Management Committee of the Corporation.

About Andrew (Andy) Sheldon

Mr. Sheldon has been President and Chief Executive Officer of Medicago since August 2003. He has thirty years of experience in the pharmaceutical industry, and was named CEO of the Year by the Vaccine Industry Excellence awards at the World Vaccine Congress in April 2012. Before joining Medicago, Mr. Sheldon was Vice-President, Sales and Marketing of Shire Biologics, where he was responsible for international expansion with European, American and Asian private partnership agreements and was also responsible for distribution, customer service, and conflicts of interest and engineering at the Shire facility. From 1998 to 2000, he was Senior Manager of Commercial Operations where he successfully managed the approval of a bladder cancer therapeutic vaccine by the FDA. In 1997 and 1998, he was Marketing Manager for Merial Canada Inc. From 1992 to 1997, he was Director of Canadian Operations with Rhône Mérieux. From 1988 to 1992, he was National Sales Manager for SmithKline Beecham. Mr. Sheldon has a Bachelor's degree in agricultural sciences from Université Laval, Québec City and a Bachelor's of science degree with honors in biological sciences from the University of East Anglia, Norwich, England.

About Jacques Simoneau

Dr. Jacques Simoneau is a corporate director with a comprehensive experience in venture capital and private equity. Prior to joining Gestion Univalor L.P. as President and Chief Executive Officer, he was Executive Vice President, Investments of the Business Development Bank of Canada ("BDC"). In that capacity, he was responsible for the venture capital and subordinate financing portfolios. Prior to that, he was President and CEO of Hydro-Québec CapiTech Inc., Senior Vice-President of the Fonds de solidarité FTQ and CEO of Société Innovatech du sud du Québec. He also held executive positions at Advanced Scientific Computing and Alcan. Dr. Simoneau is a director of Transat A.T., a public $3.5 billion international holiday travel company, of Azimut Exploration, a public Canadian mineral exploration company, and of Sustainable Development Technology Canada. He serves on the scientific committee of the Centre québécois de recherche et de développementde l'aluminium and on the University of Montréal's Faculty of Medicine's advisory committee. Dr. Simoneau was a member of the Conseil de la science et de la technologie duQuébec from 2004 to 2011, and was also director of three other public companies and 14 private companies between 1995 and now. Jacques Simoneau is a mechanical engineer and holds a M.Sc. from Université Laval and a Ph.D. from Queen's University. He is a member of the Ordre des ingénieursdu Québec, of Professional Engineers Ontario and he is certified ICD.D by the Institute of Corporate Directors.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched the PrevistageTM GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and granted the worldwide exclusive rights to this test to Signal Genetics in June 2011. The Corporation has also granted a worldwide exclusive license agreement to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. (NASDAQ: HOLX) operating as Hologic Gen-Probe, for the development and commercialization of a prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States. For more information, visit www.diagnocure.com.

Forwardlooking statements

This release contains forwardlooking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forwardlooking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forwardlooking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forwardlooking statements contained herein unless required by the applicable securities laws and regulations.


Back to news